MOSCOW, January 13. /TASS/. Over 2,000 volunteers have been administered the second dose of the Russian EpiVacCorona vaccine developed by the Vector State Research Center, Russia’s official anti-coronavirus web portal reported on Wednesday. It was noted that no adverse reactions caused by the vaccine were detected.
In all, six series of the vaccine were introduced into civilian circulation, with the total reaching 45,130 doses. The vaccine is injected intramuscularly in two phases with a 2-3 week interval.
"As of January 11, two doses of the vaccine were received by 132 volunteers within the framework of post-registration trials for participants over 60 years of age and by 2,099 volunteers within the framework of multicenter post-registration trials with the participation of 3,000 volunteers," the statement reads.
On July 24, the Vector State Research Center of Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing obtained the Healthcare Ministry’s permit to conduct clinical trials of its vaccine on volunteers. They were completed on September 30. On October 14, Russian President Vladimir Putin reported that the vaccine developed by the Vector State Research Center had obtained the registration certificate. On November 16, the Healthcare Ministry issued a permit to conduct post-registration trials of the Center’s EpiVacCorona vaccine against the coronavirus on 150 volunteers over the age of 60 and on November 18 - a permit for trials on 3,000 volunteers.